BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

Core Insights - BriaCell Therapeutics Corp. has announced that its personalized immunotherapy Bria-OTS has successfully cleared safety evaluations in a Phase 1/2 study and has begun dosing patients in combination with a checkpoint inhibitor for metastatic breast cancer [1][6] Company Developments - Bria-OTS is a next-generation version of Bria-IMT™, currently in a pivotal Phase 3 trial, aimed at enhancing immune responses against tumors [2] - The transition to the checkpoint inhibitor combination cohort follows a successful three-patient monotherapy safety run-in, with the first monotherapy patient showing complete resolution of lung metastasis [2][6] - The ongoing study will evaluate Bria-OTS in combination with a checkpoint inhibitor in up to 12 patients, focusing on safety and objective response rate (ORR) as primary endpoints [3][6] Future Plans - BriaCell plans to further assess Bria-OTS+™, an optimized version of the platform, across multiple cancer types, including breast and prostate cancers [3]